Coeptis Therapeutics Expands Immuno-Oncology Pipeline with GEAR™ Platform
• COEP forms GEAR Therapeutics, a majority-owned subsidiary, aimed at advancing GEAR-modified natural killer (NK) cells into first-in-human studies targeting various cancers.
COEPTIS, Inc. (Nasdaq: COEP), a progressive leader in biotechnology focused on innovative health solutions, recently announced a significant milestone in its journey. The company has successfully acquired exclusive worldwide development and commercialization rights to the groundbreaking GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform. This innovative approach is set to transform treatment for patients with hematologic malignancies and other cancers by optimizing cancer-targeting immune cells to increase the likelihood of achieving complete remission.
Initially, Coeptis held limited co-development rights for GEAR. Under a recent agreement with VyGen-Bio, Inc., Coeptis established GEAR Therapeutics, Inc., its new majority-owned subsidiary, tasked with advancing GEAR-based cell therapies. The company's goal is to initiate proof-of-concept studies involving GEAR-modified natural killer cells (GEAR-NK) to evaluate their effectiveness across a varied spectrum of cancers.
Innovative Mechanism of GEAR-NK Cells
The GEAR-NK technology represents a significant advancement in cancer treatment methodologies. These Gene-Edited Antibody Resistant NK cells are engineered to enhance the efficacy of traditional therapies. By allowing GEAR-NK cells to be used in conjunction with targeted monoclonal antibodies (mAbs), Coeptis aims to overcome the challenges faced by NK cells that would otherwise be neutralized by mAb therapy due to receptor overlap between malignant cells and NK cells.
This strategic combination could lead to improved treatment outcomes for patients by preventing the eradication of NK cells during therapy. Furthermore, the GEAR platform holds promise for modifying hematopoietic stem cells (HSCs) alongside mAbs to enhance the success rates of bone marrow transplants, expanding the options available for treating a variety of hematological cancers.
Expert Insights on GEAR Technology
Dr. Evren Alici, a prominent member of the COEP Scientific Advisory Board, emphasized the innovative nature of GEAR-based immunotherapy. He stated, “This approach may optimize existing antibody-centric cancer therapies, such as those using CD38 mAbs to treat multiple myeloma. By targeting specific sites, we can facilitate the co-administration of GEAR-modified NK cells with antibodies while minimizing detrimental side effects associated with traditional therapies.”
According to Dr. Alici, the encouraging results from pre-clinical proof-of-concept trials suggest that GEAR-NK strategies may effectively reduce the incidence of NK cell fratricide, thereby enhancing the clinical outcomes for patients undergoing treatment.
CEO's Vision for GEAR Technology
Excitement about GEAR's potential is expressed by Dave Mehalick, CEO of COEPTIS. He remarked, “The expanded ownership of this cutting-edge technology marks a significant success for us. The market potential for GEAR is vast, driven by a critical therapeutic need. Integrating GEAR into our allogeneic cellular immunotherapy platform could result in a beneficial and cost-effective treatment option accessible to more patients.”
About VyGen-Bio, Inc.
VyGen-Bio, Inc. operates in Florida, USA, and Stockholm, Sweden, as a majority-owned subsidiary of Vycellix, Inc. The company’s revolutionary platforms are rooted in the research from the esteemed Cell & Gene Therapy Group at Karolinska Institutet (KI). Additionally, VyGen-Bio collaborates with NextGenNK, an international competence center for developing advanced NK cell-based immunotherapies.
Coeptis’ Commitment to Innovative Therapies
Coeptis, along with its subsidiaries—Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies—strives to redefine biopharmaceutical development. Focusing on innovative cell therapies targeting cancer, autoimmune disorders, and infectious diseases, Coeptis is committed to enhancing treatment methodologies and improving patient care outcomes through its extensive research efforts.
The company’s therapeutic portfolio includes assets licensed from Deverra Therapeutics, which encompasses an allogeneic cellular immunotherapy platform. COEPTIS is also engaged in developing a universal CAR technology from the University of Pittsburgh alongside GEAR cell therapy, aiming to revolutionize cancer treatment in partnership with VyGen-Bio and renowned researchers.
In addition to its therapeutic advancements, COEPTIS has recently launched a Technology Division concentrating on refining operational functions through innovative technologies. This division incorporates AI-driven marketing solutions and robotic process automation tools designed to enhance business processes and overall productivity.
Based in Wexford, PA, COEPTIS is dedicated to adhering to the standards set by the FDA, ensuring compliance and prioritizing patient care in all its endeavors. For more detailed insights about Coeptis, please visit their official website.
Frequently Asked Questions
What is the primary focus of Coeptis Therapeutics?
Coeptis Therapeutics primarily focuses on developing innovative cell therapy platforms for treating various diseases, including cancer and autoimmune disorders.
What is the GEAR™ Cell Therapy Platform?
The GEAR™ Cell Therapy Platform enables the modification of immune cells to enhance their cancer-targeting abilities, aiming for better patient outcomes.
How does GEAR-NK differ from traditional NK cells?
GEAR-NK cells are designed to resist neutralization by monoclonal antibodies, making them more effective when used alongside conventional therapies.
Who is leading the research and development of GEAR technology?
Research and development for GEAR technology is led by prominent scientists associated with institutions like Karolinska Institutet and experts from Coeptis.
Where is Coeptis Therapeutics headquartered?
Coeptis Therapeutics is headquartered in Wexford, Pennsylvania, and is focused on maintaining high compliance and patient care standards.
